Solifenacin

Introduction Overview

Generic Name

Solifenacin

Brand Name

VESIcare, VESIcare LS

Dosage Form

Tablets (5 mg, 10 mg), Oral suspension (5 mg/5 mL)

Drug Class

Urinary antispasmodics

Pharmacokinetics

Absorption:
Solifenacin is well absorbed from the gastrointestinal tract after oral administration, with bioavailability approximating 90%. Peak plasma concentrations occur within 3 to 8 hours post-dose, demonstrating relatively slow absorption kinetics. Food intake does not significantly affect the extent of absorption although it can delay the time to peak concentration. The drug's oral suspension formulation retains similar bioavailability to tablet forms, supporting flexible administration, especially in pediatric populations. Clinical studies have confirmed consistent systemic exposure across populations when the medication is administered as prescribed.

Distribution:
Solifenacin is extensively distributed throughout the body, with a high volume of distribution averaging approximately 600 liters, indicative of extensive tissue binding. Plasma protein binding is high, approximately 98%, primarily to albumin, limiting free drug availability in systemic circulation but contributing to a prolonged half-life. The drug crosses the blood-brain barrier to a limited extent, consistent with peripheral muscarinic receptor selectivity and minimizing central nervous system adverse effects. Distribution into breast milk has been reported, necessitating caution during lactation.

Metabolism:
Solifenacin undergoes extensive hepatic metabolism primarily via the cytochrome P450 3A4 (CYP3A4) enzyme system. The metabolic pathways include oxidative metabolism to several metabolites, some of which are pharmacologically active but present at lower systemic levels compared to the parent compound. The hepatic metabolism is subject to interindividual variability influenced by CYP3A4 activity, with dosage adjustments recommended when co-administered with strong CYP3A4 inhibitors such as ketoconazole. The liver's Child-Pugh classification influences drug metabolism; moderate hepatic impairment necessitates dose reduction, and severe impairment contraindicates use.

Elimination:
The elimination half-life of solifenacin ranges from 45 to 68 hours, supporting once-daily dosing. Excretion is primarily renal, with approximately 69% of the dose eliminated via urine either as parent drug or metabolites, and the remainder via feces. In patients with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m2), elimination is decreased, requiring dose adjustment. The drug and metabolites accumulate minimally with repeated dosing in patients with normal renal and hepatic function. Steady-state levels are typically reached within one week of dosing. Monitoring in special populations is essential to avoid accumulation and toxicity.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 5 mg and 10 mg solifenacin succinate tablets
- Oral suspension (liquid): 5 mg/5 mL solifenacin succinate (VESIcare LS)

Dosages for Adults and Adolescents:
- Adults: Initial dose is usually 5 mg once daily orally, with potential titration up to 10 mg once daily based on efficacy and tolerability.
- Dose adjustments should be made cautiously in cases of renal or hepatic impairment, and when co-administered with CYP3A4 inhibitors.
- Tablets must be swallowed whole, with or without food; they should never be crushed or chewed.

Specific Patient Populations:
- Pediatric patients aged 2 years and older with neurogenic detrusor overactivity can be treated with the oral suspension formulation in weight-based dosages, starting at a recommended initial dose as per body weight, with titration as needed.
- Solifenacin tablets (5 mg and 10 mg) are not approved for pediatric use.
- Patients with severe renal impairment or moderate hepatic impairment should not exceed 5 mg once daily.
- Use contraindicated in severe hepatic impairment (Child-Pugh C).
- Dose adjustments recommended for patients concurrently using strong CYP3A4 inhibitors; do not exceed 5 mg once daily in such cases.

Mechanism Of Action

Solifenacin is a competitive antagonist of the muscarinic acetylcholine receptors, with high selectivity for the M3 receptor subtype predominant in smooth muscle of the bladder detrusor muscle. By binding to these receptors, solifenacin inhibits acetylcholine-mediated contraction of the detrusor muscle, leading to muscle relaxation. This decrease in muscular tone increases bladder capacity and reduces the frequency and urgency of micturition.

At the cellular level, solifenacin acts on G protein-coupled muscarinic receptors, preventing receptor activation and subsequent intracellular calcium mobilization essential for smooth muscle contraction. This antagonism reduces unsolicited detrusor contractions responsible for overactive bladder symptoms, such as urgency and incontinence.

Compared to other antimuscarinics like oxybutynin and tolterodine, solifenacin exhibits greater selectivity for the M3 receptor, which may confer a more favorable side effect profile by minimizing effects on non-target receptor subtypes such as M1 (neuronal) and M2 (cardiac). This selectivity is supported by clinical data showing reduced central nervous system and dry mouth adverse effects.

Clinical studies demonstrate that solifenacin improves urinary urgency, frequency, and incontinence episodes in overactive bladder and neurogenic detrusor overactivity, confirming the clinical relevance of its mechanism. Additionally, its long half-life allows for once-daily dosing, enhancing patient compliance. Ongoing research explores its potential neuroprotective benefits due to selective muscarinic receptor modulation.

Pharmacological Actions

Selective competitive antagonist of muscarinic M3 receptors in bladder smooth muscle.
Reduces detrusor muscle overactivity leading to increased bladder capacity.
Inhibits acetylcholine-induced contractions in the urinary bladder.
Decreases urinary urgency, frequency, and episodes of urge incontinence.
Exhibits higher selectivity for M3 over M1 and M2 receptors, minimizing off-target effects.
Once-daily dosing enabled by prolonged elimination half-life and sustained receptor binding.
Minimal central nervous system penetration, reducing cognitive side effect risk.
Exhibits efficacy in both idiopathic overactive bladder and neurogenic detrusor overactivity.
Metabolized by CYP3A4, important for predicting drug interactions.
Demonstrates dose-dependent pharmacodynamic effects and tolerability.
Can modulate bladder sensory pathways indirectly through muscarinic receptor inhibition.
Reduces involuntary bladder contractions by modulating intracellular calcium signaling.
Provides improved quality of life by controlling overactive bladder symptoms.
Synergistic activity potential with beta-3 adrenergic agonists in bladder management.
Approved for use in adult and pediatric populations with certain urinary disorders.

Therapeutic Or Clinical Uses

Treatment of overactive bladder symptoms including urinary urgency, frequency, and urge incontinence in adults.
Management of neurogenic detrusor overactivity (NDO) in pediatric patients aged 2 years and older.
Reducing urinary leakage episodes to improve patient quality of life.
Adjunct therapy for bladder dysfunction related to neurological diseases involving brain or spinal cord damage.
Treatment option for patients intolerant or unresponsive to other antimuscarinics.
Symptomatic relief in patients with idiopathic detrusor overactivity.
Used clinically to increase bladder storage capacity by reducing involuntary contractions.
Potential off-label use in other bladder hyperactivity disorders under specialist guidance.
Approved for daily maintenance therapy to control symptoms and prevent recurrence.
Therapeutic alternative for patients with contraindications to other urinary antispasmodic agents.
Improves bladder emptying cycles by modulating detrusor muscle activity.
Combined with behavioral therapies for comprehensive overactive bladder management.
Used for patients requiring long-term pharmacotherapy for chronic bladder dysfunction.
Reduces nocturia episodes associated with overactive bladder.
Can decrease urgency and frequency symptoms contributing to urinary incontinence.

Side Or Adverse Effects

Dry mouth, a common anticholinergic side effect related to salivary gland inhibition.
Blurred vision due to transient accommodation disturbances.
Constipation resulting from reduced gastrointestinal motility.
Dry eyes and discomfort due to decreased lacrimal gland secretions.
Heat stroke symptoms including decreased sweating, dry skin, dizziness, and fatigue.
Painful urination or dysuria reported in some patients.
Headache, confusion, drowsiness, or hallucinations, particularly in elderly or sensitive individuals.
Vision changes including eye pain and halos around lights, potential signs of acute angle-closure glaucoma.
Severe allergic reactions such as hives, facial swelling, or breathing difficulties (anaphylaxis).
Severe skin reactions including fever, sore throat, painful rash with blistering or peeling (Stevens-Johnson syndrome).
Urinary retention or difficulty emptying the bladder, sometimes requiring medical intervention.
Nausea, weakness, chest pain, tingling feelings potentially indicative of hyperkalemia.
Potential dehydration signs due to decreased sweating, requiring monitoring during hot weather or exercise.
Constipation lasting longer than 3 days with severe abdominal pain.
Rare instances of increased intraocular pressure necessitating drug discontinuation.

Precautions

Use cautiously in patients with untreated or uncontrolled narrow-angle glaucoma due to risk of increased intraocular pressure.
Monitor carefully in patients with liver or kidney impairment; dose adjustments required.
Avoid use in patients with gastrointestinal obstruction or severe gastrointestinal motility disorders.
Exercise caution in patients susceptible to urinary retention or with known difficulty emptying the bladder.
Evaluate cardiac history, especially in patients with long QT syndrome or concomitant QT-prolonging drugs.
Avoid concomitant use with potent CYP3A4 inhibitors or adjust dose accordingly to prevent toxicity.
Use with caution in elderly patients who may be more sensitive to anticholinergic burden and central nervous system effects.
Pregnancy safety has not been established; avoid use unless benefits outweigh risks.
Not recommended during breastfeeding due to potential excretion into breast milk and unknown effects on the infant.
Advise patients to avoid activities requiring mental alertness until effects on cognition and vision are known.
Monitor for signs of heat stroke during warm weather and advise adequate hydration.
Ensure proper medication adherence to avoid symptomatic relapse or adverse effects.
Patients with moderate hepatic impairment should not exceed 5 mg daily dosing.
Not to be used in severe hepatic impairment (Child-Pugh C) due to risk of accumulation and toxicity.
Inform patients about the possibility of dry mouth and recommend supportive oral care measures.

Warnings

Contraindicated in patients with untreated or uncontrolled narrow-angle glaucoma.
Avoid use if there is any known hypersensitivity to solifenacin or its inactive ingredients.
Not to be used in patients with known urinary retention or inability to empty the bladder.
Contraindicated in patients with gastrointestinal obstructive conditions such as gastric or intestinal blockage.
Use is not recommended in patients with severe hepatic impairment (Child-Pugh C).
Concomitant use with strong CYP3A4 inhibitors requires dose limitation to 5 mg once daily to prevent toxicity.
Risk of heat stroke due to reduced sweating; patients must be advised on avoidance of overheating.
May impair mental alertness and visual acuity; patients should exercise caution when driving or operating machinery.
Potential serious side effects include severe allergic reactions and Stevens-Johnson syndrome.
Overdose can be life-threatening, manifesting as severe anticholinergic effects requiring urgent medical attention.
Careful monitoring advised in patients with pre-existing cardiac conduction abnormalities.
Discontinue immediately if signs of severe abdominal pain, prolonged constipation, or vision disturbances occur.
Use in pregnancy only if clearly needed and benefits outweigh risks as fetal safety data are insufficient.
Not established for safety in pediatric patients under 2 years old; liquid formulation approved for ages 2 and above only.
Regular medical supervision required to assess efficacy and side effect profile during treatment.

Contraindication

Known hypersensitivity to solifenacin succinate or any component of the formulation.
Untreated or uncontrolled narrow-angle glaucoma.
Urinary retention or inability to empty the bladder.
Gastrointestinal obstruction or conditions causing gastric or intestinal blockage.
Severe hepatic impairment classified as Child-Pugh C.
Use in neonates or pediatric patients under 2 years old.
Co-administration with potent CYP3A4 inhibitors without dose adjustment.
Patients with known hypersensitivity to other anticholinergic agents with similar chemical structure.

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) increase solifenacin plasma concentrations; maximum dose should not exceed 5 mg daily when co-administered.
Concomitant use with other anticholinergic drugs may potentiate anticholinergic side effects such as dry mouth, blurred vision, confusion, and urinary retention.
Drugs prolonging QT interval may have additive cardiac conduction effects when used with solifenacin; monitor ECG as clinically indicated.
Co-administration with digoxin may necessitate monitoring due to potential altered gastrointestinal motility affecting digoxin absorption.
Concomitant use with cholinergic agents may theoretically antagonize the pharmacological effects of solifenacin.
Drugs affecting CYP3A4 enzyme activity may alter solifenacin metabolism leading to variability in plasma levels and therapeutic effect.
Interactions with antihistamines and tricyclic antidepressants can exacerbate anticholinergic adverse effects.
Avoid simultaneous use with agents that decrease gastrointestinal motility due to compounded risk of constipation and ileus.
Caution when combining with CNS depressants; possible increased sedation or dizziness.
Colchicine and other drugs with narrow therapeutic index metabolized by CYP3A4 require cautious monitoring with solifenacin.
Potential interaction with alcohol leading to increased sedation and impaired cognitive function.
Co-administration with beta-3 adrenergic agonists has demonstrated safety but clinical monitoring recommended.
Use with caution when combined with drugs affecting renal function due to altered elimination profiles.
No clinically significant interaction reported with commonly used antihypertensives, but patient monitoring is prudent.
Patient medication history should be thoroughly reviewed to identify and mitigate possible drug-drug interactions.

Preparations Of The Drug

Solifenacin succinate tablets available in 5 mg and 10 mg strengths, for oral administration under brand name VESIcare and generics.
Oral suspension formulation (VESIcare LS) containing 5 mg of solifenacin per 5 mL designed for pediatric patients and those with swallowing difficulties.
Tablets contain inactive ingredients such as lactose monohydrate, corn starch, hypromellose 2910, magnesium stearate, talc, polyethylene glycol 8000, titanium dioxide, and ferric oxides (yellow for 5 mg and red for 10 mg tablets).
Oral suspension contains inactive ingredients including polacrilin potassium, methylparaben, propylparaben, propylene glycol, simethicone emulsion, carbomer homopolymer Type B, xylitol, acesulfame potassium, natural orange flavor, sodium hydroxide, and purified water.
Tablets are designed to be swallowed whole and are not intended to be crushed, chewed, or broken to maintain integrity and biological availability.
Oral suspension requires shaking prior to dosing to ensure uniform drug suspension; dosing syringes or calibrated measuring devices are recommended.
Storage recommendations include maintaining tablets between 59°F to 86°F (15°C to 30°C) in a tightly closed container.
Oral suspension should be stored at room temperature between 68°F to 77°F (20°C to 25°C) with the cap tightly closed and discarded 28 days after opening.
Packaging often includes child-resistant features to prevent accidental ingestion.
Available through prescription only, with generic options accessible in many regions to improve availability.
Supply forms include bottles for oral suspension and blister or bottle packaging for tablets to facilitate distribution and adherence.
Manufactured and distributed by Astellas Pharma US, Inc., ensuring compliance with regulatory standards for potency and purity.
Patient information leaflets are provided with packaging detailing indications, dosage, side effect profiles, and administration instructions.
Both preparation forms are subject to FDA approval and post-marketing surveillance to monitor safety and efficacy.
Available in branded and generic formulations with equivalent pharmaceutical quality and bioequivalence.